Milestone Capital manages the Milestone China Opportunities Fund I, L.P., the Milestone China Opportunities Fund II, L.P., the Milestone
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Milestone Capital manages the Milestone China Opportunities Fund I, L.P., the Milestone China Opportunities Fund II, L.P., the Milestone China Opportunities Fund III, L.P. (the “Funds”), as well as the Milestone Kunshan Investment Fund, L.P. (the “RMB Fund”) which invest primarily in established high-growth companies seeking expansion or acquisition capital in China. The Funds seek to maximize medium to long term capital appreciation by making direct investments to acquire minority or majority equity stakes in those companies identified by Milestone’s investment team. The Funds’ investment size typically ranges between US$ 10 million to US$ 100 million. The RMB Fund’s investment size ranges between RMB 20 million to RMB 80 million. The Funds invest in a limited number of portfolio companies where the Milestone Capital team can dedicate significant resources to each portfolio company. Milestone Capital’s success formula is predicated on proprietary deal flows, professional due diligence, disciplined investment approach, creative structuring and proactive monitoring with a focus on value creation. Milestone Capital usually requires board representation and stringent shareholder protection commensurate with its shareholding. Milestone Capital has a strong track record in helping portfolio companies list on either domestic or foreign stock exchanges. We leverage our extensive network of advisors, industry executives, portfolio companies as well as business relationships to bring superior value-added support to our portfolio companies from both financial and strategic angles.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2014 | TalkingData | Series B | - |
10/2011 | Ushi | Series B | 3M |
5/2019 | No-Antibiotics | Series A | 2.9M |
6/2014 | Eden Biologics | Series B | 0 |
6/2008 | Suzhou Xiexin Photovoltaic Technology Co., Ltd | Series A | 260M |
1/2019 | Jousing Medical | Series A | 0 |
8/2018 | Navid Biotech | Angel Round | 290k |
5/2015 | Eden Biologics | Series C | 0 |
3/2011 | The Thatched Cottage Pharmaceutical Group | Venture Round | - |
10/2010 | Ushi | Series A | 0 |
5/2019 | ChainNews | Angel Round | - |
7/2022 | Breton | Series C | - |
9/2011 | Xinhua Travel | Series A | 23M |
4/2015 | Lili &a; Beauty | Series B | 100M |
2/2016 | Mallcoo | Series B | 3.1M |
4/2004 | Focus Media | Series C | - |
8/2016 | Spiriyo | Angel Round | 449.2k |
4/2014 | Kuke Music | Series A | 1.6M |
7/2010 | Nanjing Guanya Power Equipment | Series B | 12M |
1/2019 | Jiuxin Medical | Series A | 3M |
7/2016 | ASLAN Pharmaceuticals | Series D | 0 |
1/2014 | Happy Industry | Series A | 1.6M |
7/2022 | Breton | Series C | - |
5/2019 | ChainNews | Angel Round | - |
5/2019 | No-Antibiotics | Series A | 0 |
1/2019 | Jousing Medical | Series A | 0 |
8/2018 | Navid Biotech | Angel Round | 0 |
8/2016 | Spiriyo | Angel Round | 0 |
7/2016 | ASLAN Pharmaceuticals | Series D | 0 |
2/2016 | Mallcoo | Series B | 0 |
5/2015 | Eden Biologics | Series C | 0 |
4/2015 | Lili &a; Beauty | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|